Pro Dex Inc Quick Ratio (PDEX) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Pro dex Inc   (NASDAQ: PDEX)

Pro Dex Inc 's Quick Ratio

PDEX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Pro Dex Inc 's Cash & cash equivalent, this led to improvement in Pro Dex Inc 's Quick Ratio to 0.81, Quick Ratio remained below Pro dex Inc average.

Within Medical Equipment & Supplies industry 119 other companies have achieved higher Quick Ratio than Pro Dex Inc in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 276 to 2163.

Explain Quick Ratio?
How much Cash & cash equivalents PDEX´s has?
What are PDEX´s Current Liabilities?




PDEX Quick Ratio (Jun 30 2026)
Q4
(Mar 31 2026)
Q3
(Dec 31 2025)
Q2
(Sep 30 2025)
Q1
(Jun 30 2025)
Q4
Y / Y Current Liabilities Change -10.55 % -3.08 % 17.01 % 30.24 % 49.12 %
Y / Y Cash & cash equivalent Change 29.21 % 11.01 % 4.54 % 34.95 % 19.14 %
Quick Ratio MRQ 0.81 0.75 0.62 1.07 0.56
PDEX's Total Ranking # 2163 # 276 # 882 # 1676 # 1982
Seq. Current Liabilities Change -10.59 % 27.05 % 16.91 % -32.64 % -3.13 %
Seq. Cash & cash equivalent Change -3.98 % 53.36 % -32.16 % 29.33 % -17.5 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 120
Healthcare Sector # 669
Overall Market # 2163


Quick Ratio Statistics
High Average Low
6.02 1.74 0.18
(Sep 30 2018)   (Dec 31 2022)




Financial Statements
Pro Dex Inc 's Current Liabilities $ 13 Millions Visit PDEX's Balance sheet
Pro Dex Inc 's Cash & cash equivalent $ 11 Millions Visit PDEX's Balance sheet
Source of PDEX's Sales Visit PDEX's Sales by Geography


Cumulative Pro Dex Inc 's Quick Ratio

PDEX's Quick Ratio for the trailling 12 Months

PDEX Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 4.15 % 19.65 % 45.13 % 53.97 % 55.56 %
Y / Y Cash & cash equivalent TTM Growth 19.92 % 17.33 % 22 % 33.6 % 51.27 %
Quick Ratio TTM 0.8 0.73 0.7 0.72 0.69
Total Ranking TTM # 4068 # 643 # 2504 # 3048 # 3065
Seq. Current Liabilities TTM Growth -3.05 % -0.91 % 3.39 % 4.85 % 11.39 %
Seq. Cash & cash equivalent TTM Growth 6.47 % 3.05 % 0.88 % 8.35 % 4.17 %


On the trailing twelve months basis PDEX Cash & cash equivalent grew by 29.21 % in Q4 2026 year on year, while Current Liabilities fell to $13 millions, this led to increase in in Pro Dex Inc 's Quick Ratio to 0.8, Quick Ratio remained below PDEX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 205 other companies have achieved higher Quick Ratio than Pro Dex Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 643 to 4068.

Explain Quick Ratio?
How much Cash & cash equivalents PDEX´s has?
What are PDEX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 206
Healthcare Sector # 907
Within the Market # 4068


trailing twelve months Quick Ratio Statistics
High Average Low
2.42 0.97 0.1
(Mar 31 2019)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
EBR Systems, Inc.  2.18 $ 113.533  Millions$ 52.023  Millions
Medinotec Inc   2.15 $ 2.519  Millions$ 1.171  Millions
Atricure Inc   2.05 $ 167.786  Millions$ 81.916  Millions
Tactile Systems Technology Inc   1.83 $ 69.853  Millions$ 38.253  Millions
Tandem Diabetes Care Inc   1.80 $ 455.996  Millions$ 253.005  Millions
Inspire Medical Systems inc   1.79 $ 127.761  Millions$ 71.282  Millions
Warby Parker Inc   1.79 $ 292.674  Millions$ 163.480  Millions
Capsovision Inc   1.76 $ 9.077  Millions$ 5.158  Millions
Anika Therapeutics Inc   1.73 $ 38.412  Millions$ 22.147  Millions
Genedx Holdings Corp   1.71 $ 132.548  Millions$ 77.648  Millions
Beta Bionics Inc   1.70 $ 44.318  Millions$ 26.017  Millions
Merit Medical Systems Inc  1.70 $ 450.906  Millions$ 264.933  Millions
Seastar Medical Holding Corp  1.60 $ 6.959  Millions$ 4.353  Millions
Tela Bio Inc   1.59 $ 30.424  Millions$ 19.080  Millions
Conexeu Sciences Inc   1.55 $ 1.971  Millions$ 1.272  Millions
Inogen Inc   1.49 $ 105.539  Millions$ 70.864  Millions
Dariohealth Corp   1.49 $ 14.254  Millions$ 9.578  Millions
Myomo Inc   1.45 $ 15.686  Millions$ 10.805  Millions
Envoy Medical Inc   1.43 $ 19.679  Millions$ 13.807  Millions
Nephros Inc   1.40 $ 4.697  Millions$ 3.344  Millions
Envista Holdings Corporation  1.39 $ 1,125.600  Millions$ 807.300  Millions
Medtronic Plc  1.36 $ 16,068.000  Millions$ 11,799.000  Millions
Sanara Medtech Inc   1.31 $ 16.421  Millions$ 12.494  Millions
Globus Medical Inc   1.24 $ 595.142  Millions$ 479.347  Millions
Lucid Diagnostics Inc   1.21 $ 33.404  Millions$ 27.516  Millions
Sintx Technologies Inc   1.21 $ 3.590  Millions$ 2.977  Millions
Vaso Corporation  1.17 $ 38.291  Millions$ 32.863  Millions
Koru Medical Systems Inc   1.15 $ 8.288  Millions$ 7.180  Millions
Precision Optics Corporation Inc   1.11 $ 9.841  Millions$ 8.828  Millions
Establishment Labs Holdings Inc   1.10 $ 71.157  Millions$ 64.558  Millions

Date modified: 2026-09-05T07:51:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.